Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase. Sy SKB, Yang Y, Darstein C, Yoon DY, et al. Cancer Chemother Pharmacol 2025;95:83.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sy SKB, Yang Y, Darstein C, Yoon DY, et al. Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase. Cancer Chemother Pharmacol 2025;95:83.
PMID: 40848059